


5

CLAIMS

1. A compound of the formula 1



or a pharmaceutically acceptable salt, solvate or prodrug thereof, wherein:

m is an integer from 0 to 3;

10 p is an integer from 0 to 4;

each R<sup>1</sup> and R<sup>2</sup> is independently selected from H and C<sub>1</sub>-C<sub>6</sub> alkyl;

R<sup>3</sup> is -(CR<sup>1</sup>R<sup>2</sup>)<sub>t</sub>(4 to 10 membered heterocyclic), wherein t is an integer from 0 to 5, said heterocyclic group is optionally fused to a benzene ring or a C<sub>5</sub>-C<sub>8</sub> cycloalkyl group, the -(CR<sup>1</sup>R<sup>2</sup>)<sub>t</sub>- moiety of the foregoing R<sup>3</sup> group optionally includes a carbon-carbon double or triple bond where t is an integer between 2 and 5, and the foregoing R<sup>3</sup> groups, including any optional fused rings referred to above, are optionally substituted by 1 to 5 R<sup>8</sup> groups;

15 R<sup>4</sup> is -(CR<sup>16</sup>R<sup>17</sup>)<sub>m</sub>-C≡C-(CR<sup>16</sup>R<sup>17</sup>)<sub>t</sub>R<sup>9</sup>, -(CR<sup>16</sup>R<sup>17</sup>)<sub>m</sub>-C=C-(CR<sup>16</sup>R<sup>17</sup>)<sub>t</sub>-R<sup>9</sup>, -(CR<sup>16</sup>R<sup>17</sup>)<sub>m</sub>-C≡C-(CR<sup>16</sup>R<sup>17</sup>)<sub>k</sub>R<sup>13</sup>, -(CR<sup>16</sup>R<sup>17</sup>)<sub>m</sub>-C=C-(CR<sup>16</sup>R<sup>17</sup>)<sub>k</sub>R<sup>13</sup>, or -(CR<sup>16</sup>R<sup>17</sup>)<sub>t</sub>R<sup>9</sup>, wherein the attachment point to R<sup>9</sup> is through a carbon atom of the R<sup>9</sup> group, each k is an integer from 1 to 3, each t is an integer from 0 to 5, and each m is an integer from 0 to 3;

20 each R<sup>5</sup> is independently selected from halo, hydroxy, -NR<sup>1</sup>R<sup>2</sup>, C<sub>1</sub>-C<sub>6</sub> alkyl, trifluoromethyl, C<sub>1</sub>-C<sub>6</sub> alkoxy, trifluoromethoxy, -NR<sup>6</sup>C(O)R<sup>1</sup>, -C(O)NR<sup>6</sup>R<sup>7</sup>, -SO<sub>2</sub>NR<sup>6</sup>R<sup>7</sup>, -NR<sup>6</sup>C(O)NR<sup>7</sup>R<sup>1</sup>, and -NR<sup>6</sup>C(O)OR<sup>7</sup>;

25 each R<sup>6</sup>, R<sup>6a</sup> and R<sup>7</sup> is independently selected from H, C<sub>1</sub>-C<sub>6</sub> alkyl, -(CR<sup>1</sup>R<sup>2</sup>)<sub>t</sub>(C<sub>6</sub>-C<sub>10</sub> aryl), and -(CR<sup>1</sup>R<sup>2</sup>)<sub>t</sub>(4 to 10 membered heterocyclic), wherein t is an integer from 0 to 5, 1 or 2 ring carbon atoms of the heterocyclic group are optionally substituted with an oxo (=O) moiety, the alkyl, aryl and heterocyclic moieties of the foregoing R<sup>6</sup> and R<sup>7</sup> groups are optionally substituted with 1 to 3 substituents independently selected from halo, cyano, nitro, -NR<sup>1</sup>R<sup>2</sup>, trifluoromethyl, trifluoromethoxy, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>2</sub>-C<sub>6</sub> alkenyl, C<sub>2</sub>-C<sub>6</sub> alkynyl, hydroxy, and C<sub>1</sub>-C<sub>6</sub> alkoxy;

30 or R<sup>6</sup> and R<sup>7</sup>, or R<sup>6a</sup> and R<sup>7</sup>, when attached to the same nitrogen atom, can be taken together to form a 4 to 10 membered heterocyclic ring which may include 1 to 3 additional

5 hetero moieties, in addition to the nitrogen to which said  $R^6$ ,  $R^{6a}$ , and  $R^7$  are attached, selected from N, N( $R^1$ ), O, and S, provided two O atoms, two S atoms or an O and S atom are not attached directly to each other;

each  $R^8$  is independently selected from oxo (=O), halo, cyano, nitro, trifluoromethoxy, trifluoromethyl, azido, hydroxy,  $C_1$ - $C_6$  alkoxy,  $C_1$ - $C_{10}$  alkyl,  $C_2$ - $C_6$  alkenyl,  $C_2$ - $C_6$  alkynyl, 10  
 $-C(O)R^6$ ,  $-C(O)OR^6$ ,  $-OC(O)R^6$ ,  $-NR^6C(O)R^7$ ,  $-NR^6SO_2NR^7R^1$ ,  $-NR^6C(O)NR^1R^7$ ,  $-NR^6C(O)OR^7$ ,  
 $-C(O)NR^6R^7$ ,  $-NR^6R^7$ ,  $-NR^6OR^7$ ,  $-SO_2NR^6R^7$ ,  $-S(O)_j(C_1$ - $C_6$  alkyl) wherein j is an integer from 0 to 2,  $-(CR^1R^2)_i(C_6$ - $C_{10}$  aryl),  $-(CR^1R^2)_i(4$  to 10 membered heterocyclic),  
 $-(CR^1R^2)_qC(O)(CR^1R^2)_i(C_6$ - $C_{10}$  aryl),  $-(CR^1R^2)_qC(O)(CR^1R^2)_i(4$  to 10 membered heterocyclic),  
 $-(CR^1R^2)_iO(CR^1R^2)_q(C_6$ - $C_{10}$  aryl),  $-(CR^1R^2)_iO(CR^1R^2)_q(4$  to 10 membered heterocyclic),  
15  $-(CR^1R^2)_qS(O)_j(CR^1R^2)_i(C_6$ - $C_{10}$  aryl), and  $-(CR^1R^2)_qS(O)_j(CR^1R^2)_i(4$  to 10 membered heterocyclic), wherein j is 0, 1 or 2, q and t are each independently an integer from 0 to 5, 1 or 2 ring carbon atoms of the heterocyclic moieties of the foregoing  $R^8$  groups are optionally substituted with an oxo (=O) moiety, and the alkyl, alkenyl, alkynyl, aryl and heterocyclic moieties of the foregoing  $R^8$  groups are optionally substituted with 1 to 3 substituents  
20 independently selected from halo, cyano, nitro, trifluoromethyl, trifluoromethoxy, azido,  $-OR^6$ ,  $-C(O)R^6$ ,  $-C(O)OR^6$ ,  $-OC(O)R^6$ ,  $-NR^6C(O)R^7$ ,  $-C(O)NR^6R^7$ ,  $-NR^6R^7$ ,  $-NR^6OR^7$ ,  $C_1$ - $C_6$  alkyl,  $C_2$ - $C_6$  alkenyl,  $C_2$ - $C_6$  alkynyl,  $-(CR^1R^2)_i(C_6$ - $C_{10}$  aryl), and  $-(CR^1R^2)_i(4$  to 10 membered heterocyclic), wherein t is an integer from 0 to 5;

$R^9$  is a non-aromatic mono-cyclic ring, a fused or bridged bicyclic ring, or a spirocyclic ring, wherein said ring contains from 3 to 12 carbon atoms in which from 0 to 3 carbon atoms are optionally replaced with a hetero moiety independently selected from N, O, S(O), wherein j is an integer from 0 to 2, and  $-NR^1$ -, provided that two O atoms, two S(O), moieties, an O atom and a S(O), moiety, an N atom and an S atom, or an N atom and an O atom are not attached directly to each other within said ring, and wherein the carbon atoms of said ring are optionally substituted with 1 or 2  $R^8$  groups;

each  $R^{11}$  is independently selected from the substituents provided in the definition of  $R^8$ , except  $R^{11}$  is not oxo(=O);

$R^{12}$  is  $R^6$ ,  $-OR^6$ ,  $-OC(O)R^6$ ,  $-OC(O)NR^6R^7$ ,  $-OCO_2R^6$ ,  $-S(O)_jR^6$ ,  $-S(O)_jNR^6R^7$ ,  $-NR^6R^7$ ,  $-NR^6C(O)R^7$ ,  $-NR^6SO_2R^7$ ,  $-NR^6C(O)NR^{6a}R^7$ ,  $-NR^6SO_2NR^{6a}R^7$ ,  $-NR^6CO_2R^7$ , CN,  $-C(O)R^6$ , or 35  
halo, wherein j is an integer from 0 to 2;

$R^{13}$  is  $-NR^1R^{14}$  or  $-OR^{14}$ ;

$R^{14}$  is H,  $R^{15}$ ,  $-C(O)R^{15}$ ,  $-SO_2R^{15}$ ,  $-C(O)NR^{15}R^7$ ,  $-SO_2NR^{15}R^7$ , or  $-CO_2R^{15}$ ;

$R^{15}$  is  $R^{18}$ ,  $-(CR^1R^2)_i(C_6$ - $C_{10}$  aryl),  $-(CR^1R^2)_i(4$  to 10 membered heterocyclic), wherein t is an integer from 0 to 5, 1 or 2 ring carbon atoms of the heterocyclic group are optionally

5 substituted with an oxo (=O) moiety, and the aryl and heterocyclic moieties of the foregoing  $R^{15}$  groups are optionally substituted with 1 to 3  $R^8$  substituents;

each  $R^{16}$  and  $R^{17}$  is independently selected from H,  $C_1$ - $C_6$  alkyl, and  $-CH_2OH$ , or  $R^{16}$  and  $R^{17}$  are taken together as  $-CH_2CH_2-$  or  $-CH_2CH_2CH_2-$ ;


10  $R^{18}$  is  $C_1$ - $C_6$  alkyl wherein each carbon not bound to a N or O atom, or to  $S(O)_j$ , wherein j is an integer from 0 to 2, is optionally substituted with  $R^{12}$ ;

and wherein any of the above-mentioned substituents comprising a  $CH_3$  (methyl),  $CH_2$  (methylene), or CH (methine) group, which is not attached to a halogeno, SO or  $SO_2$  group or to a N, O or S atom, is optionally substituted with a group selected from hydroxy, halo,  $C_1$ - $C_4$  alkyl,  $C_1$ - $C_4$  alkoxy and  $-NR^1R^2$ .

15 2. A compound according to claim 1 wherein  $R^3$  is  $-(CR^1R^2)_t$  (4 to 10 membered heterocyclic), wherein t is an integer from 0 to 5; said heterocyclic group is optionally fused to a benzene ring or a  $C_5$ - $C_8$  cycloalkyl group, and the foregoing  $R^3$  groups, including any optional fused rings referred to above, are optionally substituted by 1 to 3  $R^8$  groups.

20 3. A compound according to claim 1 wherein  $R^3$  is  $-(CR^1R^2)_t$  (4 to 10 membered heterocyclic), wherein t is an integer from 0 to 5, and the foregoing  $R^3$  groups are optionally substituted by 1 to 3  $R^8$  groups.


4. A compound according to claim 1 wherein  $R^3$  is selected from



wherein the foregoing  $R^3$  groups are optionally substituted by 1 to 3  $R^8$  groups.

25 5. A compound according to claim 1 wherein  $R^3$  is pyridin-3-yl optionally substituted by 1 to 3  $R^8$  groups.

6. A compound according to claim 1 wherein the following structural portion of the compound of formula 1



5

is selected from the group consisting of

3-Methyl-4-(pyridin-2-yloxy)-phenylamino

3-Chloro-4-(pyridin-2-yloxy)-phenylamino

3-Methoxy-4-(pyridin-2-yloxy)-phenylamino

10

4-(pyridin-2-yloxy)-phenylamino

2-Methyl-4-(pyridin-2-yloxy)-phenylamino

2-Methoxy-4-(pyridin-2-yloxy)-phenylamine

3-Chloro-4-(6-methyl-pyridin-2-yloxy)-phenylamino

3-Methoxy-4-(6-methyl-pyridin-2-yloxy)-phenylamino

15

3-Methyl-4-(6-methyl-pyridin-2-yloxy)-phenylamino

2-Methoxy-4-(6-methyl-pyridin-2-yloxy)-phenylamino

2-Methyl-4-(6-methyl-pyridin-2-yloxy)-phenylamino

4-(6-methyl-pyridin-2-yloxy)-phenylamino

3-Methoxy-4-(2-methyl-pyridin-3-yloxy)-phenylamino

20

3-Methyl-4-(2-methyl-pyridin-3-yloxy)-phenylamino

3-Chloro-4-(2-methyl-pyridin-3-yloxy)-phenylamino

2-Methoxy-4-(2-methyl-pyridin-3-yloxy)-phenylamino

2-Methyl-4-(2-methyl-pyridin-3-yloxy)-phenylamino

4-(2-methyl-pyridin-3-yloxy)-phenylamino

25

3-Methyl-4-(6-methyl-pyridin-3-yloxy)-phenylamino

3-Chloro-4-(6-methyl-pyridin-3-yloxy)-phenylamino

3-Methoxy-4-(6-methyl-pyridin-3-yloxy)-phenylamino

2-Methyl-4-(6-methyl-pyridin-3-yloxy)-phenylamino

2-Methoxy-4-(6-methyl-pyridin-3-yloxy)-phenylamino

30

4-(6-methyl-pyridin-3-yloxy)-phenylamino

3-Methyl-4-(pyridin-3-yloxy)-phenylamino

3-Chloro-4-(pyridin-3-yloxy)-phenylamino

3-Methoxy-4-(pyridin-3-yloxy)-phenylamino

2-Methyl-4-(pyridin-3-yloxy)-phenylamino

35

2-Methoxy-4-(pyridin-3-yloxy)-phenylamino

4-(pyridin-3-yloxy)-phenylamino

- 5        3-Methyl-4-(2-methyl-pyrimidin-5-yloxy)-phenylamino  
          3-Chloro-4-(2-methyl-pyrimidin-5-yloxy)-phenylamino  
          3-Methoxy-4-(2-methyl-pyrimidin-5-yloxy)-phenylamino  
          2-Methyl-4-(2-methyl-pyrimidin-5-yloxy)-phenylamino  
          2-Methoxy-4-(2-methyl-pyrimidin-5-yloxy)-phenylamino  
10       4-(2-methyl-pyrimidin-5-yloxy)-phenylamino  
          3-Methyl-4-(4-methyl-pyrimidin-5-yloxy)-phenylamino  
          3-Chloro-4-(4-methyl-pyrimidin-5-yloxy)-phenylamino  
          3-Methoxy-4-(4-methyl-pyrimidin-5-yloxy)-phenylamino  
          2-Methyl-4-(4-methyl-pyrimidin-5-yloxy)-phenylamino  
15       2-Methoxy-4-(4-methyl-pyrimidin-5-yloxy)-phenylamino  
          4-(4-methyl-pyrimidin-5-yloxy)-phenylamino  
          3-Methyl-4-(2-methyl-pyridin-4-yloxy)-phenylamino  
          3-Chloro-4-(2-methyl-pyridin-4-yloxy)-phenylamino  
          3-Methoxy-4-(2-methyl-pyridin-4-yloxy)-phenylamino  
20       2-Methyl-4-(2-methyl-pyridin-4-yloxy)-phenylamino  
          2-Methoxy-4-(2-methyl-pyridin-4-yloxy)-phenylamino  
          4-(2-methyl-pyridin-4-yloxy)-phenylamino  
          3-Methyl-4-(pyridin-4-yloxy)-phenylamino  
          3-Chloro-4-(pyridin-4-yloxy)-phenylamino  
25       3-Methoxy-4-(pyridin-4-yloxy)-phenylamino  
          2-Methyl-4-(pyridin-4-yloxy)-phenylamino  
          2-Methoxy-4-(pyridin-4-yloxy)-phenylamino  
          4-(pyridin-4-yloxy)-phenylamino  
          3-Methyl-4-(2-methyl-pyrimidin-4-yloxy)-phenylamino  
30       3-Methoxy-4-(2-methyl-pyrimidin-4-yloxy)-phenylamino  
          3-Chloro-4-(2-methyl-pyrimidin-4-yloxy)-phenylamino  
          2-Methyl-4-(2-methyl-pyrimidin-4-yloxy)-phenylamino  
          2-Methoxy-4-(2-methyl-pyrimidin-4-yloxy)-phenylamino  
          4-(2-methyl-pyrimidin-4-yloxy)-phenylamino  
35       3-Methyl-4-(6-methyl-pyrimidin-4-yloxy)-phenylamino  
          3-Methoxy-4-(6-methyl-pyrimidin-4-yloxy)-phenylamino  
          3-Chloro-4-(6-methyl-pyrimidin-4-yloxy)-phenylamino  
          2-Methyl-4-(6-methyl-pyrimidin-4-yloxy)-phenylamino  
          2-Methoxy-4-(6-methyl-pyrimidin-4-yloxy)-phenylamino  
40       4-(6-methyl-pyrimidin-4-yloxy)-phenylamino

5	3-Methyl-4-(pyrazin-2-yloxy)-phenylamino
	3-Methoxy-4-(pyrazin-2-yloxy)-phenylamino
	3-Chloro-4-(pyrazin-2-yloxy)-phenylamino
	2-Methyl-4-(pyrazin-2-yloxy)-phenylamino
	2-Methoxy-4-(pyrazin-2-yloxy)-phenylamino
10	4-(pyrazin-2-yloxy)-phenylamino
	3-Chloro-4-(3-methyl-pyrazin-2-yloxy)-phenylamino
	3-Methoxy-4-(3-methyl-pyrazin-2-yloxy)-phenylamino
	3-Methyl-4-(3-methyl-pyrazin-2-yloxy)-phenylamino
	2-Methoxy-4-(3-methyl-pyrazin-2-yloxy)-phenylamino
15	2-Methyl-4-(3-methyl-pyrazin-2-yloxy)-phenylamino
	4-(3-methyl-pyrazin-2-yloxy)-phenylamino
	3-Chloro-4-(5-methyl-pyrazin-2-yloxy)-phenylamino
	3-Methoxy-4-(5-methyl-pyrazin-2-yloxy)-phenylamino
	3-Methyl-4-(5-methyl-pyrazin-2-yloxy)-phenylamino
20	2-Methoxy-4-(5-methyl-pyrazin-2-yloxy)-phenylamino
	2-Methyl-4-(5-methyl-pyrazin-2-yloxy)-phenylamino
	4-(5-methyl-pyrazin-2-yloxy)-phenylamino
	3-Chloro-4-(6-methyl-pyrazin-2-yloxy)-phenylamino
	3-Methoxy-4-(6-methyl-pyrazin-2-yloxy)-phenylamino
25	3-Methyl-4-(6-methyl-pyrazin-2-yloxy)-phenylamino
	2-Methoxy-4-(6-methyl-pyrazin-2-yloxy)-phenylamino
	2-Methyl-4-(6-methyl-pyrazin-2-yloxy)-phenylamino
	4-(6-methyl-pyrazin-2-yloxy)-phenylamino
	3-Methyl-4-(pyridazin-3-yloxy)-phenylamino
30	3-Chloro-4-(pyridazin-3-yloxy)-phenylamino
	3-Methoxy-4-(pyridazin-3-yloxy)-phenylamino
	2-Methyl-4-(pyridazin-3-yloxy)-phenylamino
	2-Methoxy-4-(pyridazin-3-yloxy)-phenylamino
	4-(pyridazin-3-yloxy)-phenylamino
35	3-Methyl-4-(6-methyl-pyridazin-3-yloxy)-phenylamino
	3-Chloro-4-(6-methyl-pyridazin-3-yloxy)-phenylamino
	3-Methoxy-4-(6-methyl-pyridazin-3-yloxy)-phenylamino
	2-Methyl-4-(6-methyl-pyridazin-3-yloxy)-phenylamino
	2-Methoxy-4-(6-methyl-pyridazin-3-yloxy)-phenylamino
40	4-(6-methyl-pyridazin-3-yloxy)-phenylamino

- 5 3-Methyl-4-(6-methyl-pyridazin-4-yloxy)-phenylamino
- 3-Chloro-4-(6-methyl-pyridazin-4-yloxy)-phenylamino
- 3-Methoxy-4-(6-methyl-pyridazin-4-yloxy)-phenylamino
- 2-Methyl-4-(6-methyl-pyridazin-4-yloxy)-phenylamino
- 2-Methoxy-4-(6-methyl-pyridazin-4-yloxy)-phenylamino
- 10 4-(6-methyl-pyridazin-4-yloxy)-phenylamino
- 3-Methyl-4-(3-methyl-pyridazin-4-yloxy)-phenylamino
- 3-Chloro-4-(3-methyl-pyridazin-4-yloxy)-phenylamino
- 3-Methoxy-4-(3-methyl-pyridazin-4-yloxy)-phenylamino
- 2-Methyl-4-(3-methyl-pyridazin-4-yloxy)-phenylamino
- 15 2-Methoxy-4-(3-methyl-pyridazin-4-yloxy)-phenylamino
- 4-(3-methyl-pyridazin-4-yloxy)-phenylamino
- 3-Methyl-4-(pyridazin-4-yloxy)-phenylamino
- 3-Chloro-4-(pyridazin-4-yloxy)-phenylamino
- 3-Methoxy-4-(pyridazin-4-yloxy)-phenylamino
- 20 2-Methyl-4-(pyridazin-4-yloxy)-phenylamino
- 2-Methoxy-4-(pyridazin-4-yloxy)-phenylamino
- 4-(pyridazin-4-yloxy)-phenylamino
- 3-Chloro-4-(1-methyl-1H-pyrazol-4-yloxy)-phenylamino
- 3-Methoxy-4-(1-methyl-1H-pyrazol-4-yloxy)-phenylamino
- 25 3-Methyl-4-(1-methyl-1H-pyrazol-4-yloxy)-phenylamino
- 2-Methoxy-4-(1-methyl-1H-pyrazol-4-yloxy)-phenylamino
- 2-Methyl-4-(1-methyl-1H-pyrazol-4-yloxy)-phenylamino, and
- 4-(1-methyl-1H-pyrazol-4-yloxy)-phenylamino.

7. A compound according to claim 1 wherein  $R^4$  is  $-(CR^{16}R^{17})_m-C\equiv C-(CR^{16}R^{17})_tR^9$ ,  
30 wherein m is an integer from 0 to 3, and t is an integer from 0 to 5.

8. A compound according to claim 1 wherein  $R^4$  is  $-(CR^{16}R^{17})_m-C\equiv C-(CR^{16}R^{17})_tR^9$ ,  
wherein m is an integer from 0 to 3, and t is an integer from 0 to 5, wherein  $R^9$  is selected from 3-  
piperidinyl and 4-piperidinyl each of which is optionally substituted with 1 or 2  $R^8$  groups.

9. A compound according to claim 1 wherein  $R^4$  is  $-(CR^{16}R^{17})_m-C=C-(CR^{16}R^{17})_tR^9$ ,  
35 wherein m is an integer from 0 to 3, and t is an integer from 0 to 5.

10. A compound according to claim 1 wherein  $R^4$  is  $-(CR^{16}R^{17})_m-C=C-(CR^{16}R^{17})_tR^9$ ,  
wherein m is an integer from 0 to 3, and t is an integer from 0 to 5, wherein  $R^9$  is selected from 3-  
piperidinyl and 4-piperidinyl (optionally substituted with 1 or 2  $R^8$  groups).

11. A compound according to claim 1 wherein  $R^4$  is  $-(CR^{16}R^{17})_m-C\equiv C-(CR^{16}R^{17})_kR^{13}$ ,  
40 wherein k is an integer from 1 to 3 and m is an integer from 0 to 3.

5 12. A compound according to claim 1 wherein  $R^4$  is  $-(CR^{16}R^{17})_m-C\equiv C-(CR^{16}R^{17})_kR^{13}$ , wherein  $k$  is an integer from 1 to 3 and  $m$  is an integer from 0 to 3, wherein  $R^{13}$  is  $-NR^{14}$ , wherein  $R^{14}$  is selected from  $-C(O)R^{15}$ ,  $-SO_2R^{15}$ , and  $-C(O)NR^{15}R^7$ .

13. A compound according to claim 1 wherein  $R^4$  is  $-(CR^{16}R^{17})_m-C=C-(CR^{16}R^{17})_kR^{13}$ , wherein  $k$  is an integer from 1 to 3 and  $m$  is an integer from 0 to 3.

10 14. A compound according to claim 1 wherein  $R^4$  is  $-(CR^{16}R^{17})_m-C=C-(CR^{16}R^{17})_kR^{13}$ , wherein  $k$  is an integer from 1 to 3 and  $m$  is an integer from 0 to 3, wherein  $R^{13}$  is  $-NR^{14}$ , wherein  $R^{14}$  is selected from  $-C(O)R^{15}$ ,  $-SO_2R^{15}$ , and  $-C(O)NR^{15}R^7$ .

15 15. A compound according to claim 1 wherein  $R^4$  is  $-(CR^{16}R^{17})_m-C\equiv C-(CR^{16}R^{17})_kR^{13}$  or  $-(CR^{16}R^{17})_m-C=C-(CR^{16}R^{17})_kR^{13}$ , wherein  $k$  is an integer from 1 to 3 and  $m$  is an integer from 0 to 3,  $R^{13}$  is  $-NR^{14}$  or  $-OR^{14}$ ,  $R^{14}$  is  $R^{15}$ ,  $R^{15}$  is  $R^{18}$ , and  $R^{18}$  is  $C_1-C_6$  alkyl optionally substituted by  $-OR^6$ ,  $-S(O)_2R^6$ ,  $-NR^6R^7$ ,  $-NR^6C(O)R^7$ ,  $-NR^6SO_2R^7$ ,  $-NR^6CO_2R^7$ ,  $CN$ ,  $-C(O)R^6$ , or halo.

16. A compound according to claim 1 selected from the group consisting of:

(+)-[3-Methyl-4-(pyridin-3-yloxy)-phenyl]-(6-piperidin-3-ylethynyl-quinazolin-4-yl)-amine;

20 2-Methoxy-N-(3-{4-[3-methyl-4-(pyridin-3-yloxy)-phenylamino]-quinazolin-6-yl}-prop-2-ynyl)-acetamide

(+)-[3-Methyl-4-(6-methyl-pyridin-3-yloxy)-phenyl]-(6-piperidin-3-ylethynyl-quinazolin-4-yl)-amine;

25 2-Methoxy-N-(3-{4-[3-methyl-4-(2-methyl-pyridin-3-yloxy)-phenylamino]-quinazolin-6-yl}-prop-2-ynyl)-acetamide

[3-Methyl-4-(2-methyl-pyridin-3-yloxy)-phenyl]-(6-piperidin-4-ylethynyl-quinazolin-4-yl)-amine

[3-Methyl-4-(6-methyl-pyridin-3-yloxy)-phenyl]-(6-piperidin-4-ylethynyl-quinazolin-4-yl)-amine;

30 2-Methoxy-N-(3-{4-[3-methyl-4-(6-methyl-pyridin-3-yloxy)-phenylamino]-quinazolin-6-yl}-prop-2-ynyl)-acetamide;

2-Fluoro-N-(3-{4-[3-methyl-4-(6-methyl-pyridin-3-yloxy)-phenylamino]-quinazolin-6-yl}-prop-2-ynyl)-acetamide;

35 *E*-2-Methoxy-N-(3-{4-[3-methyl-4-(6-methyl-pyridin-3-yloxy)-phenylamino]-quinazolin-6-yl}-allyl)-acetamide;

[3-Methyl-4-(pyridin-3-yloxy)-phenyl]-(6-piperidin-4-ylethynyl-quinazolin-4-yl)-amine;

2-Methoxy-N-(1-{4-[3-methyl-4-(6-methyl-pyridin-3-yloxy)-phenylamino]-quinazolin-6-ylethynyl}-cyclopropyl)-acetamide;



- 5 *E*-N-(3-{4-[3-Chloro-4-(6-methyl-pyridin-3-yloxy)-phenylamino]-quinazolin-6-yl}-allyl)-2-methoxy-acetamide;  
N-(3-{4-[3-Chloro-4-(6-methyl-pyridin-3-yloxy)-phenylamino]-quinazolin-6-yl}-prop-2-ynyl)-acetamide;  
N-(3-{4-[3-Methyl-4-(6-methyl-pyridin-3-yloxy)-phenylamino]-quinazolin-6-yl}-prop-2-ynyl)-acetamide;  
10 *E*-N-(3-{4-[3-Chloro-4-(6-methyl-pyridin-3-yloxy)-phenylamino]-quinazolin-6-yl}-allyl)-acetamide;  
*E*-2-Ethoxy-N-(3-{4-[3-methyl-4-(6-methyl-pyridin-3-yloxy)-phenylamino]-quinazolin-6-yl}-allyl)-acetamide;  
15 1-Ethyl-3-(3-{4-[3-methyl-4-(6-methyl-pyridin-3-yloxy)-phenylamino]-quinazolin-6-yl}-prop-2-ynyl)-urea;  
Piperazine-1-carboxylic acid (3-{4-[3-methyl-4-(6-methyl-pyridin-3-yloxy)-phenylamino]-quinazolin-6-yl}-prop-2-ynyl)-amide;  
(+)-2-Hydroxymethyl-pyrrolidine-1-carboxylic acid (3-{4-[3-methyl-4-(6-methyl-pyridin-3-yloxy)-phenylamino]-quinazolin-6-yl}-prop-2-ynyl)-amide;  
20 2-Dimethylamino-N-(3-{4-[3-methyl-4-(pyridin-3-yloxy)-phenylamino]-quinazolin-6-yl}-prop-2-ynyl)-acetamide;  
*E*-N-(3-{4-[3-Methyl-4-(6-methyl-pyridin-3-yloxy)-phenylamino]-quinazolin-6-yl}-allyl)-methanesulfonamide;  
25 Isoxazole-5-carboxylic acid (3-{4-[3-methyl-4-(6-methyl-pyridin-3-yloxy)-phenylamino]-quinazolin-6-yl}-prop-2-ynyl)-amide;  
1-(1,1-Dimethyl-3-{4-[3-methyl-4-(6-methyl-pyridin-3-yloxy)-phenylamino]-quinazolin-6-yl}-prop-2-ynyl)-3-ethyl-urea;  
and the pharmaceutically acceptable salts, prodrugs and solvates of the foregoing  
30 compounds.
17. A method for the treatment of abnormal cell growth in a mammal comprising administering to said mammal an amount of a compound of claim 1 that is effective in treating abnormal cell growth.
- 18 A method according to claim 17 wherein said abnormal cell growth is cancer.
- 35 19. A method according to claim 18 wherein said cancer is selected from lung cancer, bone cancer, pancreatic cancer, skin cancer, cancer of the head or neck, cutaneous or intraocular melanoma, uterine cancer, ovarian cancer, rectal cancer, cancer of the anal region, stomach cancer, colon cancer, breast cancer, uterine cancer, carcinoma of the fallopian tubes, carcinoma of the endometrium, carcinoma of the cervix, carcinoma of the vagina, carcinoma of the vulva, Hodgkin's Disease, cancer of the esophagus, cancer of the small intestine, cancer of
- 40

5 the endocrine system, cancer of the thyroid gland, cancer of the parathyroid gland, cancer of the  
adrenal gland, sarcoma of soft tissue, cancer of the urethra, cancer of the penis, prostate cancer,  
chronic or acute leukemia, lymphocytic lymphomas, cancer of the bladder, cancer of the kidney  
or ureter, renal cell carcinoma, carcinoma of the renal pelvis, neoplasms of the central nervous  
system (CNS), primary CNS lymphoma, spinal axis tumors, brain stem glioma, pituitary  
10 adenoma, or a combination of one or more of the foregoing cancers.

20. A method for the treatment of abnormal cell growth in a mammal which comprises  
administering to said mammal an amount of a compound of claim 1 that is effective in treating  
abnormal cell growth in combination with an anti-tumor agent selected from the group consisting  
of mitotic inhibitors, alkylating agents, anti-metabolites, intercalating antibiotics, growth factor  
15 inhibitors, radiation, cell cycle inhibitors, enzymes, topoisomerase inhibitors, biological response  
modifiers, antibodies, cytotoxics, anti-hormones, and anti-androgens.

21. A pharmaceutical composition for the treatment of abnormal cell growth in a  
mammal comprising an amount of a compound of claim 1 that is effective in treating abnormal  
cell growth, and a pharmaceutically acceptable carrier.

20

0983752-061001